Pancreatic Cancer
Conditions
Brief summary
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
Detailed description
Single-patient, open-label clinical study: * Events during Pre-Treatment Period: 1. Resection of pancreatic cancer, 2. RNA acquisition from tumor specimen, 3. RNA amplification, 4. Infectious disease testing, 5. Autoimmune disease testing, 6. Two blood draws for immune response monitoring, 7. Production leukapheresis, and 8. Dendritic cell electroporation with RNA and immunotherapeutic production; * Events during Induction Period: 1. Administer investigative treatment every 2 weeks for a total of five doses, followed by dosing every 4 weeks for a total of four doses, 2. Two Induction Period blood draws (Week 6 and Week 12) for immune response monitoring, and 3. One leukapheresis (Week 14) for immune response monitoring; * Events during Booster Period: 1. Dose every 3 months until progression or 2 years after first AGS treatment, 2. Potentially, one leukapheresis for immune response monitoring 12 months from the first dose, and 3. One blood draw 2 weeks following dosing at Week 36 (1st booster dose) (approximately Week 38); and, * Events during study Close-Out: 1. Close-Out upon progression or 28 days following immune response monitoring 2 years after first dose
Interventions
BIOLOGICALAGS-006
Autologous Therapy for Pancreatic Cancer
Sponsors
Argos Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A male subject 18 years of age or older with newly diagnosed resectable pancreatic cancer who, in the opinion of the investigator, is suitable for participation in the study will be eligible for inclusion if all of the following criteria apply: 1. Able to abstain from taking prohibited prescription or prohibited non-prescription drugs. 2. Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements. 3. Voluntary informed consent given to participate in the study.
Exclusion criteria
1. Any serious medical condition such as cardiopulmonary disease, circulatory compromise, hepatic or renal dysfunction, or other illness considered by the investigator to constitute an unwarranted high risk for investigational treatment. 2. Active autoimmune disease including, but not limited to: 3. Active, acute, or chronic clinically significant infections including human immunodeficiency virus (HIV) and viral hepatitis. 4. Known hypersensitivity to dimethyl sulfoxide (DMSO). 5. Body weight less than 30 kg.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment-emergent changes in localized injection site reactions following each dose | — |
| Treatment-emergent changes in vital signs (blood pressure, heart rate, respiratory rate, and body temperature) from baseline values obtained prior to each investigative treatment | — |
| Incidence of treatment-emergent adverse events graded according to the Common Terminology Criteria for Adverse Events | — |
| Treatment-emergent adenopathy, tenderness, or inflammation (inguinal and axillary) assessed before and after each dose | — |
| Treatment-emergent changes in autoimmunity evaluations as measured by clinical signs and symptoms and laboratory assessments at periodic intervals during the Treatment Period. | — |
Secondary
| Measure | Time frame |
|---|---|
| T cell response to RNA-electroporated DCs will be assessed by flow cytometry using blood cells collected according to protocol time and events | — |
| Positive immune response | — |
| Feasibility | — |
| Assessment of progression-free survival (PFS) estimated from the date of subject registration - Standard Response Evaluation Criteria in Solid Tumors (RECIST) definitions of progressive disease (PD) will contribute to estimating the interval for PFS. | — |
Countries
United States
Outcome results
None listed